Summary
Boston Scientific Corporation reported a net loss of $147 million ($0.11 per diluted share) for the second quarter of 2020, a significant decline from the net income of $154 million ($0.11 per diluted share) in the same period of 2019. This downturn was primarily driven by the global COVID-19 pandemic, which led to a 23.9% decrease in net sales to $2.003 billion, as elective medical procedures were postponed. Despite the challenges, the company is taking steps to manage costs and liquidity, including debt refinancing and equity offerings, to navigate the uncertain economic environment. The first six months of 2020 also saw a net loss of $137 million compared to a net income of $578 million in the prior year, with net sales down 11.3% to $4.546 billion. The company highlighted sequential improvements in sales trends throughout the second quarter and expects continued sequential improvement into the third and fourth quarters, provided there is no resurgence of COVID-19 cases. Management has implemented cost-saving measures and believes its long-term fundamentals remain strong, supported by an innovative product pipeline.
Financial Highlights
50 data points| Revenue | $2.00B |
| Cost of Revenue | $791.00M |
| Gross Profit | $1.21B |
| SG&A Expenses | $798.00M |
| Operating Expenses | $1.28B |
| Operating Income | -$71.00M |
| Interest Expense | $91.00M |
| Net Income | -$147.00M |
| EPS (Basic) | $-0.11 |
| EPS (Diluted) | $-0.11 |
| Shares Outstanding (Basic) | 1.41B |
| Shares Outstanding (Diluted) | 1.41B |
Key Highlights
- 1Net sales for Q2 2020 decreased by 23.9% to $2.003 billion compared to $2.631 billion in Q2 2019, primarily due to the impact of the COVID-19 pandemic on elective medical procedures.
- 2The company reported a net loss of $147 million ($0.11 per diluted share) for Q2 2020, a significant decrease from a net income of $154 million ($0.11 per diluted share) in Q2 2019.
- 3For the first six months of 2020, net sales were $4.546 billion, down 11.3% from $5.124 billion in the same period of 2019.
- 4Total debt stood at $9.532 billion as of June 30, 2020, with cash and cash equivalents at $1.724 billion.
- 5In May 2020, the company completed offerings of $975 million in Mandatory Convertible Preferred Stock and $975 million in common stock, using the proceeds to repay term loan debt and for general corporate purposes.
- 6The company experienced a significant decrease in gross profit margin to 60.5% in Q2 2020 from 71.2% in Q2 2019, attributed to idle manufacturing costs and excess inventory charges related to the pandemic.
- 7Despite revenue declines, the company maintained compliance with its amended financial leverage covenant, with a leverage ratio of 3.64 times as of June 30, 2020, below the 4.75 times maximum permitted.